Navigation Links
Biomerix Corporation Receives ISO 13485 Certification
Date:6/15/2009

Company with Innovative Biomaterial Technology Achieves Significant Milestone in CE Mark Approval Pathway

FREMONT, Calif., June 15 /PRNewswire/ -- Biomerix Corporation, a medical technologies company developing products using its novel Biomerix Biomaterial(TM), a three-dimensional scaffold for biointegrative tissue repair, announced today that it has received an ISO 13485 Certificate of Registration. Issued by the British Standards Institution (BSI), the certification indicates that Biomerix has successfully implemented a quality system that conforms to the exacting International Organization for Standardization (ISO) standards for medical devices. ISO is one of the key regulatory requirements for a CE Mark in the European Union as well as other international markets. The certification applies to the Fremont, CA location which designs, manufactures and distributes finished medical devices and the Somerset, NJ location which manufactures the Biomerix Biomaterial.

ISO 13485 is an internationally recognized standardization system which defines standards for the design, development, production and distribution of medical devices. It ensures conformity with specified quality controls in the development of safe and effective devices. Achievement of ISO 13485:2003 demonstrates Biomerix Corporation's dedication to continuously improve product quality by providing finished medical devices and polymer components that consistently meet customer and regulatory requirements.

"This certification represents a major milestone for Biomerix Corporation and demonstrates our unwavering commitment to producing high-quality devices for our customers. Meeting the ISO standards speaks to our belief in our quality management system and is an important step towards commercialization abroad," commented Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation.

About Biomerix Corporation

Biomerix Corporation develops and manufactures a broad portfolio of implantable medical devices based on its proprietary Biomerix Biomaterial(TM) platform technology. Constructed as an ideal biointegrative scaffold, the Biomerix Biomaterial supports tissue repair and regeneration, leading to better clinical outcomes. Biomerix strives to improve patient outcomes through the development of medical devices for soft tissue repair, neurovascular embolization, spine annular repair, cardiovascular repair and women's health indications, utilizing its innovative Biomaterial.

For more information call 888.308.3620 or visit www.biomerix.com


'/>"/>
SOURCE Biomerix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Providence Service Corporation Announces Preliminary Results of Annual Meeting of Stockholders
2. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
3. Hospital Corporation of America Named to Computerworlds Annual List of Best Places to Work in Information Technology
4. Genaera Corporation Board of Directors Dissolves Corporation and Forms Liquidating Trust
5. Zix Corporation Announces Review of Strategic Alternatives for e-Prescribing Business
6. Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer
7. Sabinsa Corporation Validates Safety of Garcinia Cambogia Extract in Light of Hydroxycut Warning
8. RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card
9. Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17, 2009
10. Genaera Corporation Announces Results of Special Meeting of Stockholders
11. Angelica Corporation Raises Bar Again for Increased Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... RU (PRWEB) , ... June 26, 2017 , ... ... released a whitepaper that pledges to solve many catastrophic issues within funding campaigns. ... 2017. , The typical notion of crowdfunding - the raising of funds through the ...
(Date:6/25/2017)... ... ... FCPX LUT Vintage Volume 2 for Final Cut Pro X allows users ... contains 60 different color-grade presets, giving editors multiple options for adding different color options. ... subjects, plus much more. FCPX LUT Vintage Volume 2 is designed for any skill-set ...
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version of ... differs significantly from the American Health Care Act, which the House passed in May, ... will have to take up the Senate version as-is, if it passes. , The ...
(Date:6/25/2017)... ... , ... CareSet Labs released the Root NPI Graph today at the 2017 ... improved version of the Doctor Referral teaming dataset commonly available from Medicare. , Originally ... the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by ...
(Date:6/25/2017)... ... 2017 , ... June is Men’s Health Month and the focus is on prostate ... in the U.S. and the third most common cause of cancer related death today; lung ... seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology: